MedTrace Logo

Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)

NCT01705626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-06-06

No results posted yet for this study

Summary

An International, multicenter, epidemiological observational study investigating the prevalence of Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR-FAP) in participants with small fiber polyneuropathy of no obvious etiology.

Conditions

  • Polyneuropathy, Amyloid
  • Neuropathic Pain
  • Cardiac Failure
  • Orthostatic Hypotension
  • Gastrointestinal Disorders

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Peter Bauer, Prof. · Centogene GmgH

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2022-05-27
Completion
2022-05-27

Countries

  • Austria
  • Hungary
  • North Macedonia
  • Poland
  • Serbia
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01705626 on ClinicalTrials.gov